ArticleJournal of clinical medicine2019

Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.

Chiara Napoletano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.